AUTHORS
Lanzhu Yue, MD, PhD, Vladimir Otasevic, MD, PhD2, Ying Li3, Ingrida Savickaite-Guobuze4, Nancy Lunney VI, MA5, Heidi Cho, MD6
AFFILIATIONS
1 Parexel International, Shanghai, China
2 Parexel International, Shanghai, China
3 Parexel International, Shanghai, China
4 Parexel International, Shanghai, China
5 Parexel International, Shanghai, China
6 Parexel International, Shanghai, China
ABSTRACT
Background: Bispecific antibodies (BsAbs) targeting BCMA and GPRC5D have emerged as transformative therapeutic options for multiple myeloma (MM) patients. Direct comparisons of BCMA- and GPRC5D-targeted BsAbs remain limited, particularly among patients previously exposed to BCMA-directed therapy - a clinically important population who may develop BCMA antigen loss leading to reduced effectiveness of subsequent BCMA-targeted treatments. This analysis aims to evaluate the overall survival (OS) and safety profile of GPRC5D- versus BCMA-targeted BsAbs in MM patients using real-world data, with stratification by prior BCMA-directed therapy exposure, to inform treatment sequencing decisions in BCMA-exposed patients.
Methods: A retrospective cohort study was conducted using the TriNetX USA network on July 27, 2026, to identify MM patients who have received either BCMA (teclistamab, elranatamab) or GPRC5D BsAb (talquetamab) as index therapy. Three predefined cohorts were assessed: the overall population, BCMA-naïve patients (without prior BCMA-targeted therapy), and BCMA-exposed patients (with prior BCMA-targeted therapy, including ciltacabtagene autoleucel, idecabtagene vicleucel or belantamab mafodotin). Propensity score matching (PSM) was performed to balance baseline prognostic covariates between treatment groups. Primary outcomes include OS and risk of death, analyzed using Kaplan-Meier curves with log-rank test and hazard ratios (HR) with 95% confidence intervals (CI). Secondary outcomes include the incidence of CRS (cytokine release syndrome), ICANS (immune effector cell-associated neurotoxicity syndrome), severe infections and intensive care unit (ICU) admission, assessed using risk ratios (RR) with 95% CI.
Results: A total of 2860 MM patients were identified, including 2210 patients who received BCMA-targeted BsAbs (teclistamab, elranatamab) and 650 patients who received GPRC5D-targeted BsAb (talquetamab). In the overall unmatched cohort, while OS showed no significant difference between groups (HR 0.844, 95% CI 0.703-1.015, p=0.07), risk of death at 3-year follow-up was significantly lower in the GPRC5D group compared to the BCMA group (RR 0.836, 95% CI 0.715-0.977, p=0.02). PSM was performed for baseline covariates, including age, sex, BMI, ECOG, extramedullary disease, prior bone marrow transplantation and renal function. In the matched cohort (640 patients per group), the GPRC5D group demonstrated significant survival benefit compared to the BCMA group (survival probability at 3 years: 61.78% vs. 58.04%, log-rank test p=0.027; HR 0.781, 95% CI 0.626-0.973). Any-grade CRS (40.63% vs 21.88%, p<0.0001) or ICANS (17.19% vs 9.38%, p<0.0001) within 60 days of treatment initiation was significantly more frequent in the GPRC5D group, while severe infections (p=0.32) and ICU admission rates (p=0.32) were comparable between both groups.
We further performed subgroup analysis stratified by prior BCMA-directed therapy exposure. Interestingly, survival benefit diverged significantly based on prior BCMA exposure, while CRS and ICANS remained more frequent in GPRC5D group, and severe infections/ICU admission rates remained comparable between the two groups. In BCMA-naïve patients (530 patients per group), no significant difference in OS was observed between GPRC5D and BCMA groups (HR=0.873, 95% CI 0.681–1.119, p=0.28). In BCMA-exposed patients (90 patients per group), GPRC5D group demonstrated significantly superior OS compared to BCMA group (median OS: not reached vs. 639 days; survival probability at 3 years: 66.17% vs. 44.74%, log-rank test p=0.0168; HR=0.515, 95%CI 0.296–0.896). This subgroup represented the primary driver of the OS advantage observed in the overall matched population.
Conclusion: In this real-world study, GPRC5D-targeted BsAb was associated with superior overall survival compared with BCMA-targeted BsAbs, with the benefit driven predominantly by patients previously exposed to BCMA-directed therapy. These findings support sequential GPRC5D-targeted therapy as a favorable option for MM patients with prior BCMA exposure despite higher rates of CRS and ICANS. The superior survival of GPRC5D BsAb in BCMA-exposed patients likely reflects its ability to overcome resistance mechanisms associated with prior BCMA-directed therapy such as BCMA antigen loss. Prospective randomized trials are warranted to validate these findings and guide clinical decision-making in BCMA-exposed MM patients.
DISCLOSURES
Lanzhu Yue, MD, PhD: No relevant conflicts of interest to declare.